Data as of 3:59pm ET
| -0.02 / -1.20%|
The 2 analysts offering 12-month price forecasts for KaloBios Pharmaceuticals Inc have a median target of 7.50, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +354.55% increase from the last price of 1.65.
The current consensus among 4 polled investment analysts is to Buy stock in KaloBios Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.